ClinicalTrials.gg
CompletedNCT06045221ACHIEVE-3Updated Sep 15, 2026Results posted

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

A Phase 3 interventional study of Orforglipron and Semaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 131 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,698
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
2nd of 15
1,698 · median 546
Started
2023
with 5 others
Phase 3
11 of 15
2 open now
Registered
8th of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes
  • Have ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol), as determined by the central laboratory at screening.
  • Have been on stable diabetes treatment with metformin ≥1500 milligram (mg)/day during the 90 days prior to screening and maintained through randomization.
  • Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema, for example, laser photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors.
  • Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening, or between screening and randomization.
  • Have a functional classification IV congestive heart failure.
  • Have an estimated (eGFR) \<45 milliliter/minute (mL/min)/1.73 square meter (m²) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory at screening.
  • Have a serum calcitonin level of ≥35 nanogram/Liter (ng/L), as determined by the central laboratory at screening.
  • Have a history of an active or untreated or are in remission from a malignancy for less than 5 years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,698 participants (actual)

Study arms

  • Experimental
    12 mg Orforglipron

    Participants initiated treatment with a 1 mg once-daily oral dose of orforglipron and increased the dose every 4 weeks until the targeted dose of 12 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron

    Participants initiated treatment with a 1 mg once-daily oral dose of orforglipron and increased the dose every 4 weeks until the targeted dose of 36 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    Drug: Orforglipron

  • Active comparator
    7 mg Semaglutide

    Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 7 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    Drug: Semaglutide

  • Active comparator
    14 mg Semaglutide

    Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 14 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]

    * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 12 mg Orforglipron Versus 14 mg Semaglutide, Superiority of 12 mg and 36 mg Orforglipron Versus 7 mg and 14 mg Semaglutide]

    * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  2. Percentage of Participants Who Achieved HbA1c <7.0% [53 Millimoles/Mole (mmol/Mol)]

    The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

    Time frame: Week 52

  3. Percentage of Participants Who Achieved HbA1c <=6.5% (48 mmol/Mol)

    The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

    Time frame: Week 52

  4. Percentage of Participants Who Achieved HbA1c <5.7% (39 mmol/Mol)

    The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

    Time frame: Week 52

  5. Percent Change From Baseline in Body Weight

    LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  6. Change From Baseline in Body Weight

    LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  7. Change From Baseline in Fasting Serum Glucose

    LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  8. Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)

    The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  9. Percentage of Participants Who Achieved Weight Loss of >=5%

    The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

    Time frame: Week 52

  10. Percentage of Participants Who Achieved Weight Loss of >=10%

    The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

    Time frame: Week 52

  11. Percentage of Participants Who Achieved Weight Loss of >=15%

    The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

    Time frame: Week 52

  12. Change From Baseline in Systolic Blood Pressure (SBP)

    LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  13. Change From Baseline in Diastolic Blood Pressure (DBP)

    LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  14. Percent Change From Baseline in Total Serum Cholesterol

    LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  15. Percent Change From Baseline in Serum Low Density Lipoprotein (LDL) Cholesterol

    LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  16. Percent Change From Baseline in Serum Non High Density Lipoprotein (Non-HDL) Cholesterol

    LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  17. Percent Change From Baseline in Serum Triglycerides

    LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  18. Percent Change From Baseline in Serum High Density Lipoprotein (HDL) Cholesterol

    LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  19. Percent Change From Baseline in Serum Very Low Density Lipoprotein (VLDL) Cholesterol

    LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    Time frame: Baseline, Week 52

  20. Change From Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form (Physical Component and Mental Component Scores)

    The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the physical component summary and mental component summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 52

07

Results

Posted Sep 15, 2026

Participant flow

Participant flow — Overall Study
Milestone12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Started424423426425
Received at least one dose of study drug424423426425
Completed382380388401
Not completed42433824
Withdrew: Adverse event7445
Withdrew: Withdrawal by subject19221610
Withdrew: Lost to follow-up91093
Withdrew: Physician decision1113
Withdrew: Death1120
Withdrew: Non-compliance with study drug2000
Withdrew: Pregnancy0200
Withdrew: Protocol deviation1010
Withdrew: Other - as reported by the investigator2353

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]

* HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]
Percentage of HbA1c12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]-1.91 ± 0.058-2.16 ± 0.051-1.11 ± 0.063-1.45 ± 0.061
Statistical analysis
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -0.71 · 95% CI -0.86 to -0.55
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -0.79 · 95% CI -0.96 to -0.62
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 12 mg Orforglipron Versus 14 mg Semaglutide, Superiority of 12 mg and 36 mg Orforglipron Versus 7 mg and 14 mg Semaglutide]

* HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 12 mg Orforglipron Versus 14 mg Semaglutide, Superiority of 12 mg and 36 mg Orforglipron Versus 7 mg and 14 mg Semaglutide]
Percentage of HbA1c12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 12 mg Orforglipron Versus 14 mg Semaglutide, Superiority of 12 mg and 36 mg Orforglipron Versus 7 mg and 14 mg Semaglutide]-1.91 ± 0.058-2.16 ± 0.051-1.11 ± 0.063-1.45 ± 0.061
Statistical analysis
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -0.46 · 95% CI -0.62 to -0.29
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -0.79 · 95% CI -0.96 to -0.62
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -1.04 · 95% CI -1.2 to -0.88
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -0.46 · 95% CI -0.62 to -0.29
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -0.71 · 95% CI -0.86 to -0.55
SecondaryPercentage of Participants Who Achieved HbA1c <7.0% [53 Millimoles/Mole (mmol/Mol)]

The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved HbA1c <7.0% [53 Millimoles/Mole (mmol/Mol)]
percentage of participants12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percentage of Participants Who Achieved HbA1c <7.0% [53 Millimoles/Mole (mmol/Mol)]80.04 ± 1.9785.41 ± 1.8054.63 ± 2.4566.12 ± 2.27
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 25.41 · 95% CI 19.34 to 31.49
  • 12 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 13.92 · 95% CI 8.10 to 19.74
  • 36 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 30.78 · 95% CI 24.78 to 36.78
  • 36 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 19.29 · 95% CI 13.63 to 24.96
SecondaryPercentage of Participants Who Achieved HbA1c <=6.5% (48 mmol/Mol)

The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved HbA1c <=6.5% (48 mmol/Mol)
percentage of participants12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percentage of Participants Who Achieved HbA1c <=6.5% (48 mmol/Mol)71.76 ± 2.2676.82 ± 2.1440.87 ± 2.3850.88 ± 2.42
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 30.89 · 95% CI 24.50 to 37.28
  • 12 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 20.88 · 95% CI 14.45 to 27.30
  • 36 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 35.96 · 95% CI 29.71 to 42.20
  • 36 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 25.94 · 95% CI 19.63 to 32.25
SecondaryPercentage of Participants Who Achieved HbA1c <5.7% (39 mmol/Mol)

The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved HbA1c <5.7% (39 mmol/Mol)
percentage of participants12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percentage of Participants Who Achieved HbA1c <5.7% (39 mmol/Mol)25.44 ± 2.2437.09 ± 2.567.84 ± 1.2712.54 ± 1.64
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 17.60 · 95% CI 12.58 to 22.62
  • 12 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 12.90 · 95% CI 7.51 to 18.29
  • 36 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 29.24 · 95% CI 23.69 to 34.80
  • 36 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 24.54 · 95% CI 18.67 to 30.41
SecondaryPercent Change From Baseline in Body Weight

LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Body Weight-6.7 ± 0.34-9.2 ± 0.40-3.7 ± 0.27-5.3 ± 0.30
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -2.9 · 95% CI -3.8 to -2.1
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.002 · Least squares mean difference: -1.4 · 95% CI -2.3 to -0.5
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -5.5 · 95% CI -6.4 to -4.5
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -4.0 · 95% CI -4.9 to -3.0
SecondaryChange From Baseline in Body Weight

LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Body Weight-6.6 ± 0.34-8.9 ± 0.39-3.6 ± 0.26-5.0 ± 0.29
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -3.1 · 95% CI -3.9 to -2.2
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -1.6 · 95% CI -2.5 to -0.8
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -5.4 · 95% CI -6.3 to -4.4
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -3.9 · 95% CI -4.9 to -3.0
SecondaryChange From Baseline in Fasting Serum Glucose

LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligram per deciliter (mg/dL)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Fasting Serum Glucose-55.2 ± 1.77-60.1 ± 1.55-28.9 ± 2.49-40.2 ± 2.33
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -26.2 · 95% CI -32.3 to -20.2
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -15.0 · 95% CI -20.7 to -9.2
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -31.2 · 95% CI -37.0 to -25.4
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -19.9 · 95% CI -25.4 to -14.4
SecondaryChange From Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)

The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)
milligram per deciliter (mg/dL)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)-69.4 ± 1.60-74.9 ± 1.40-51.2 ± 2.10-61.4 ± 1.48
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -18.2 · 95% CI -23.4 to -13
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -7.9 · 95% CI -12.2 to -3.7
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -23.8 · 95% CI -28.7 to -18.8
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -13.5 · 95% CI -17.5 to -9.5
SecondaryPercentage of Participants Who Achieved Weight Loss of >=5%

The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved Weight Loss of >=5%
percentage of participants12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percentage of Participants Who Achieved Weight Loss of >=5%59.18 ± 2.5569.49 ± 2.3936.89 ± 2.5349.39 ± 2.57
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 22.29 · 95% CI 15.16 to 29.42
  • 12 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = 0.007 · Risk difference (rd): 9.79 · 95% CI 2.70 to 16.87
  • 36 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 32.60 · 95% CI 25.86 to 39.34
  • 36 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 20.09 · 95% CI 13.21 to 26.98
SecondaryPercentage of Participants Who Achieved Weight Loss of >=10%

The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved Weight Loss of >=10%
percentage of participants12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percentage of Participants Who Achieved Weight Loss of >=10%28.23 ± 2.3443.46 ± 2.5413.18 ± 1.8420.95 ± 2.08
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 15.05 · 95% CI 9.20 to 20.90
  • 12 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = 0.020 · Risk difference (rd): 7.28 · 95% CI 1.16 to 13.39
  • 36 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 30.28 · 95% CI 23.96 to 36.60
  • 36 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 22.5 · 95% CI 16.13 to 28.88
SecondaryPercentage of Participants Who Achieved Weight Loss of >=15%

The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Participants Who Achieved Weight Loss of >=15%
percentage of participants12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percentage of Participants Who Achieved Weight Loss of >=15%11.99 ± 1.6523.21 ± 2.174.99 ± 1.196.45 ± 1.25
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 7.00 · 95% CI 3.08 to 10.93
  • 12 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = 0.007 · Risk difference (rd): 5.53 · 95% CI 1.50 to 9.56
  • 36 mg Orforglipron vs 7 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 18.22 · 95% CI 13.32 to 23.13
  • 36 mg Orforglipron vs 14 mg Semaglutide · Regression, Logistic · p = <.001 · Risk difference (rd): 16.76 · 95% CI 11.86 to 21.65
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Systolic Blood Pressure (SBP)-4.5 ± 0.55-5.4 ± 0.65-2.0 ± 0.58-2.7 ± 0.59
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.002 · Least squares mean difference: -2.5 · 95% CI -4.0 to -0.9
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.024 · Least squares mean difference: -1.8 · 95% CI -3.4 to -0.2
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -3.4 · 95% CI -5.1 to -1.7
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.002 · Least squares mean difference: -2.7 · 95% CI -4.5 to -1.0
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP)

LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP)
millimeters of mercury (mmHg)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Change From Baseline in Diastolic Blood Pressure (DBP)-0.6 ± 0.390.0 ± 0.42-0.4 ± 0.39-0.3 ± 0.39
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.775 · Least squares mean difference: -0.2 · 95% CI -1.2 to 0.9
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.611 · Least squares mean difference: -0.3 · 95% CI -1.4 to 0.8
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.487 · Least squares mean difference: 0.4 · 95% CI -0.7 to 1.5
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.624 · Least squares mean difference: 0.3 · 95% CI -0.8 to 1.4
SecondaryPercent Change From Baseline in Total Serum Cholesterol

LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Total Serum Cholesterol
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Total Serum Cholesterol-4.25 ± 0.928-2.93 ± 0.920-0.50 ± 1.1490.19 ± 0.927
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.011 · Least squares mean difference: -3.77 · 95% CI -6.57 to -0.88
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -4.43 · 95% CI -6.91 to -1.89
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.097 · Least squares mean difference: -2.45 · 95% CI -5.26 to 0.45
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.017 · Least squares mean difference: -3.12 · 95% CI -5.60 to -0.57
SecondaryPercent Change From Baseline in Serum Low Density Lipoprotein (LDL) Cholesterol

LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Serum Low Density Lipoprotein (LDL) Cholesterol
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Serum Low Density Lipoprotein (LDL) Cholesterol-4.32 ± 1.643-1.93 ± 1.568-2.49 ± 1.6351.95 ± 1.753
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.430 · Least squares mean difference: -1.87 · 95% CI -6.38 to 2.85
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.009 · Least squares mean difference: -6.15 · 95% CI -10.52 to -1.57
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.804 · Least squares mean difference: 0.58 · 95% CI -3.88 to 5.24
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.098 · Least squares mean difference: -3.81 · 95% CI -8.14 to 0.72
SecondaryPercent Change From Baseline in Serum Non High Density Lipoprotein (Non-HDL) Cholesterol

LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Serum Non High Density Lipoprotein (Non-HDL) Cholesterol
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Serum Non High Density Lipoprotein (Non-HDL) Cholesterol-7.70 ± 1.213-5.48 ± 1.225-2.11 ± 1.451-1.93 ± 1.245
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.003 · Least squares mean difference: -5.71 · 95% CI -9.30 to -1.98
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -5.88 · 95% CI -9.19 to -2.44
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.075 · Least squares mean difference: -3.44 · 95% CI -7.09 to 0.36
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.042 · Least squares mean difference: -3.61 · 95% CI -6.98 to -0.13
SecondaryPercent Change From Baseline in Serum Triglycerides

LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Serum Triglycerides
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Serum Triglycerides-16.89 ± 1.698-15.95 ± 1.688-4.98 ± 2.270-13.44 ± 1.681
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -12.54 · 95% CI -17.77 to -6.98
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.149 · Least squares mean difference: -3.99 · -3.99% CI -9.15 to 1.47
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -11.55 · 95% CI -16.8 to -5.97
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.291 · Least squares mean difference: -2.91 · 95% CI -8.08 to 2.56
SecondaryPercent Change From Baseline in Serum High Density Lipoprotein (HDL) Cholesterol

LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Serum High Density Lipoprotein (HDL) Cholesterol
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Serum High Density Lipoprotein (HDL) Cholesterol6.78 ± 0.8525.40 ± 0.8803.86 ± 1.0576.33 ± 1.020
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.032 · Least squares mean difference: 2.81 · 95% CI 0.24 to 5.45
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.737 · Least squares mean difference: 0.42 · 95% CI -2.01 to 2.91
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = 0.264 · Least squares mean difference: 1.48 · 95% CI -1.10 to 4.14
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.488 · Least squares mean difference: -0.88 · 95% CI -3.32 to 1.63
SecondaryPercent Change From Baseline in Serum Very Low Density Lipoprotein (VLDL) Cholesterol

LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Serum Very Low Density Lipoprotein (VLDL) Cholesterol
Percent change12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Percent Change From Baseline in Serum Very Low Density Lipoprotein (VLDL) Cholesterol-14.87 ± 1.651-14.79 ± 1.603-5.44 ± 1.771-12.52 ± 1.647
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -9.97 · 95% CI -14.61 to -5.08
  • 12 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.316 · Least squares mean difference: -2.68 · 95% CI -7.70 to 2.62
  • 36 mg Orforglipron vs 7 mg Semaglutide · Mixed Models Analysis · p = <.001 · Least squares mean difference: -9.89 · 95% CI -14.46 to -5.07
  • 36 mg Orforglipron vs 14 mg Semaglutide · Mixed Models Analysis · p = 0.325 · Least squares mean difference: -2.59 · 95% CI -7.54 to 2.63
SecondaryChange From Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form (Physical Component and Mental Component Scores)

The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the physical component summary and mental component summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · T-score
Change From Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form (Physical Component and Mental Component Scores)
T-score12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Physical Component Score2.88 ± 0.3332.57 ± 0.3282.89 ± 0.3222.56 ± 0.324
Mental Component Score1.32 ± 0.4010.89 ± 0.4381.13 ± 0.4150.65 ± 0.437
Statistical analysis
  • 12 mg Orforglipron vs 7 mg Semaglutide · ANCOVA · p = 0.986 · Least squares mean difference: 0.01 · 95% CI -0.84 to 0.83
  • 12 mg Orforglipron vs 14 mg Semaglutide · ANCOVA · p = 0.478 · Least squares mean difference: 0.32 · 95% CI -0.56 to 1.20
  • 36 mg Orforglipron vs 7 mg Semaglutide · ANCOVA · p = 0.455 · Least squares mean difference: -0.32 · 95% CI -1.16 to 0.52
  • 36 mg Orforglipron vs 14 mg Semaglutide · ANCOVA · p = 0.990 · Least squares mean difference: 0.01 · 95% CI -0.88 to 0.89
  • 12 mg Orforglipron vs 7 mg Semaglutide · ANCOVA · p = 0.742 · Least squares mean difference: 0.18 · 95% CI -0.91 to 1.28
  • 12 mg Orforglipron vs 14 mg Semaglutide · ANCOVA · p = 0.244 · Least squares mean difference: 0.67 · 95% CI -0.46 to 1.79
  • 36 mg Orforglipron vs 7 mg Semaglutide · ANCOVA · p = 0.657 · Least squares mean difference: -0.25 · 95% CI -1.35 to 0.85
  • 36 mg Orforglipron vs 14 mg Semaglutide · ANCOVA · p = 0.691 · Least squares mean difference: 0.23 · 95% CI -0.93 to 1.39

Adverse events

Collected over Baseline to end of safety follow-up (up to 57 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12 mg Orforglipron1/424 (0.2%)21/424 (5%)278/424 (65.6%)
36 mg Orforglipron1/423 (0.2%)40/423 (9.5%)278/423 (65.7%)
7 mg Semaglutide2/426 (0.5%)19/426 (4.5%)225/426 (52.8%)
14 mg Semaglutide0/425 (0%)24/425 (5.6%)249/425 (58.6%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
Event12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1950/2180/2061/206
Abdominal painGastrointestinal disorders1/4242/4230/4260/425
AppendicitisInfections and infestations1/4242/4230/4260/425
PneumoniaInfections and infestations0/4242/4232/4261/425
Ischaemic strokeNervous system disorders2/4240/4231/4262/425
Acute myocardial infarctionCardiac disorders0/4240/4232/4261/425
HypertensionVascular disorders0/4240/4232/4260/425
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1951/2180/2060/206
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1951/2180/2060/206
Angina pectorisCardiac disorders0/4241/4230/4260/425
Most frequent other events
Showing 10 of 15
Most frequent other events
Event12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg Semaglutide
NauseaGastrointestinal disorders112/424116/42356/42690/425
DiarrhoeaGastrointestinal disorders92/42499/42356/42677/425
VomitingGastrointestinal disorders72/42470/42333/42644/425
HyperglycaemiaMetabolism and nutrition disorders25/42420/42369/42634/425
Diabetic retinopathyEye disorders57/42460/42354/42658/425
ConstipationGastrointestinal disorders56/42455/42333/42638/425
DyspepsiaGastrointestinal disorders48/42444/42318/42633/425
EructationGastrointestinal disorders42/42432/42317/42614/425
Abdominal distensionGastrointestinal disorders24/42434/42311/42614/425
Decreased appetiteMetabolism and nutrition disorders30/42429/42321/42627/425

Baseline characteristics

All randomised participants.

Age, Continuous
Age, Continuous(years)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg SemaglutideTotal
Mean54.0 ± 11.353.4 ± 11.454.9 ± 11.253.4 ± 10.553.9 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg SemaglutideTotal
Female195218206206825
Male229205220219873
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg SemaglutideTotal
Hispanic or Latino3043043163101234
Not Hispanic or Latino117117108113455
Unknown or Not Reported32229
Race (NIH/OMB)
Race (NIH/OMB)(Participants)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg SemaglutideTotal
American Indian or Alaska Native90797689334
Asian50515249202
Native Hawaiian or Other Pacific Islander00000
Black or African American1716122065
White2502592662541029
More than one race111013842
Unknown or Not Reported687526
Region of Enrollment
Region of Enrollment(Participants)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg SemaglutideTotal
Argentina145145146146582
China26252625102
Japan2020212182
Mexico123123123123492
United States110110110110440
HemoglobinA1c (HbA1c)
HemoglobinA1c (HbA1c)(Percentage of HbA1c)12 mg Orforglipron36 mg Orforglipron7 mg Semaglutide14 mg SemaglutideTotal
Mean8.27 ± 1.058.28 ± 1.118.31 ± 1.098.30 ± 1.128.29 ± 1.09
08

Study locations

131 sites
  • Absolute Clinical Research
    Phoenix, Arizona 85051, United States
  • San Fernando Valley Health Institute
    Canoga Park, California 91304, United States
  • Neighborhood Healthcare Institute of Health
    Escondido, California 92025, United States
  • Velocity Clinical Research, Gardena
    Gardena, California 90247, United States
  • Biopharma Informatic, LLC
    Los Angeles, California 90035, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Infinity Clinical Research - Norco
    Norco, California 92860, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Norcal Endocrinology & Internal Medicine
    San Ramon, California 94583, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • New West Physicians Clinical Research
    Golden, Colorado 80401, United States
  • Connecticut Clinical Research - Cromwell
    Cromwell, Connecticut 06416, United States
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
  • South Florida Clinical Research Institute
    Margate, Florida 33063, United States
  • Miami Dade Medical Research Institute, LLC
    Miami, Florida 33176, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Latin Clinical Trial Center Florida
    Tamarac, Florida 33321, United States
  • Clinical Research of West Florida
    Tampa, Florida 33606, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Balanced Life Health Care Solutions/SKYCRNG
    Lawrenceville, Georgia 30046, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Family First Medical Center
    Idaho Falls, Idaho 83404, United States
  • American Health Network of Indiana, LLC - Greenfield
    Greenfield, Indiana 46140, United States
  • Velocity Clinical Research, Valparaiso
    Valparaiso, Indiana 46383, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • Tekton Research, Inc
    Wichita, Kansas 67218, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Revival Research Institute, LLC
    Dearborn, Michigan 48126, United States
  • SKY Integrative Medical Center/SKYCRNG
    Ridgeland, Mississippi 39157, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Wr-Crcn, Llc
    Las Vegas, Nevada 89106, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Albany Medical College, Division of Community Endocrinology
    Albany, New York 12203, United States
  • Ellipsis Research Group - Brooklyn - 7th Street
    Brooklyn, New York 11215, United States
  • Great Lakes Medical Research, LLC
    Westfield, New York 14787, United States
  • PharmQuest Life Sciences, LLC
    Greensboro, North Carolina 27408, United States
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • Accellacare - Piedmont
    Statesville, North Carolina 28625, United States
  • Wake Forest University Baptist Medical Center (WFUBMC)
    Winston-Salem, North Carolina 27104, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Tekton Research, Inc
    Moore, Oklahoma 73160, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • The Corvallis Clinic, P.C.
    Corvallis, Oregon 97330, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
  • The Research Center of The Upstate
    Greenville, South Carolina 29607, United States
  • New Phase Research and Development
    Knoxville, Tennessee 37909, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • Velocity Clinical Research, Austin
    Austin, Texas 78759, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Diabetes and Thyroid Center of Ft. Worth
    Fort Worth, Texas 76132, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Endocrine Ips, Pllc
    Houston, Texas 77079, United States
  • Clear Brook Medical Associates
    Houston, Texas 77089, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
  • Synexus Clinical Research US, Inc.
    Salt Lake City, Utah 84106, United States
  • Eastside Research Associates
    Redmond, Washington 98052, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1056, Argentina
  • CIMeL
    Lanus, Buenos Aires B1824KAJ, Argentina
  • Centro de Investigaciones Médicas Mar del Plata
    Mar del Plata, Buenos Aires 7600, Argentina
  • Policlinica Red OMIP
    Mar del Plata, Buenos Aires 7600, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, Buenos Aires F.D. 1405, Argentina
  • CIPREC
    Buenos Aires, Buenos Aires F.D. C1061AAS, Argentina
  • Centro Médico Viamonte
    Buenos Aires, Buenos Aires F.D. C1120AAC, Argentina
  • Instituto Centenario
    CABA, Buenos Aires F.D. 1204, Argentina
  • Centro de Salud e Investigaciones Médicas
    Santa Rosa, La Pampa Province 6300, Argentina
  • INECO Neurociencias Oroño
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto de Especialidades de la Salud Rosario
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto Médico Catamarca IMEC
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica
    Rosario, Santa Fe Province 2000, Argentina
  • Fundacion Estudios Clinicos
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Instituto de Investigaciones Clínicas Córdoba
    Córdoba, 5000, Argentina
  • Instituto Médico DAMIC
    Córdoba, 5003DCE, Argentina
  • Sanatorio Norte
    Santiago del Estero, 4200, Argentina
  • Beijing Pinggu District Hospital
    Beijing, Beijing Municipality 101200, China
  • Chongqing General Hospital
    Chongqing, Chongqing Municipality 400014, China
  • Shunde Hospital of Southern Medical Univesity
    Foshan, Guangdong 528399, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong 516001, China
  • The Fourth Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, Henan 471003, China
  • Nanyang First People's Hospital
    Nanyang, Henan 473014, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • Dalian Municipal Central Hospital Affiliated of Dalian Medical University
    Dalian, Liaoning 116033, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality 200030, China
  • Pudong New Area People's Hospital Shanghai
    Shanghai, Shanghai Municipality 201200, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310013, China

Showing the first 100 of 131 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu WS, Liu R, Zhao Y; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026 Mar 21;407(10534):1147-1160. doi: 10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. PubMed 41765029 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Aug 2025, 23 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Sep 21, 2023
StartActual
Sep 22, 2023
Primary completionActual
Aug 22, 2025
CompletionActual
Aug 22, 2025
Results first posted
Sep 15, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06045221
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 22, 2023
Primary completion
Aug 22, 2025
Completion
Aug 22, 2025
Results posted
Sep 15, 2026
Last update
Sep 15, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion